Connect your AI

CytomX Therapeutics CTMX Earnings yield

Earnings yield at other companies

PfizerPFE

6.8%—

AmgenAMGN

4.1%+0.6pp

Janux TherapeuticsJANX

-13.5%-30.9pp

Allogene TherapeuticsALLO

-29.2%-11.3pp

Vor BiopharmaVOR

-733.6%-1,389pp

Design Therapeutics, Inc.DSGN

-10.6%-3.9pp

Other financials

Income statement

Revenue$10.3M-79.9%

Operating income-$19.7M-187%

Net income-$18.2M-178%

EPS (diluted)-$0.10-137%

Balance sheet

Cash & equivalents$28.8M-39.4%

Total debt$2.9M-65.0%

Total equity$319.9M+1,177%

Total assets$359.4M+265%

Cash flow

Operating cash flow-$25.5M-21.4%

CapEx--100%

Free cash flow-$25.5M-20.7%

Valuation

Market cap$711.89M+94.8%

Enterprise value$685.92M+110%

P/S20×+17.6×

Profitability

Operating margin-181.9%-206pp

Net margin-166.4%-195pp

FCF margin-225.6%-334pp

Returns & leverage

Return on equity-34.3%—

Debt / equity0×-0.3×

Current ratio10.4×+8.7×

Where this comes from

Calculated from CytomX Therapeutics’s reported figures.

net income/market cap=-5.8%

Based on trailing twelve months.

The official record: CytomX Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about CytomX Therapeutics's earnings yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is CytomX Therapeutics's earnings yield?: CytomX Therapeutics (CTMX) reported earnings yield of -5.8% in Q1 2026.
How has CytomX Therapeutics's earnings yield changed year-over-year?: CytomX Therapeutics's earnings yield decreased by 107.1% year-over-year, from 81.7% to -5.8%.
What is the long-term trend for CytomX Therapeutics's earnings yield?: Over 4 years (2020 to 2025), CytomX Therapeutics's earnings yield has grown at a -36.9% compound annual growth rate (CAGR), from -15.2% to -2.4%.
What does earnings yield mean?: Trailing-twelve-month net income divided by market capitalization at the quarter end — the inverse of the P/E ratio, expressed as a percentage.